Clinical Trial Update: PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC [Phase 2]

View source ↗

Summary

The PROPHET study is a Phase 2 clinical trial evaluating ctDNA-guided personalized induction immunochemotherapy for non-small cell lung cancer, currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING